Kyle Gowen

发表

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

A. Iafrate, P. Stephens, A. Shaw, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.

P. Stephens, S. Ou, Siraj M. Ali, 2016, JAMA oncology.

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

P. Stephens, J. Ross, S. Ou, 2015, Lung cancer.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Mark Rosenzweig, Joel Greshock, Doron Lipson, 2015, Cancer discovery.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Jens Meiler, Taofeek K Owonikoko, Jonathan H Sheehan, 2016, Cancer discovery.

Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion

P. Stephens, V. Miller, F. Meric-Bernstam, 2016, Oncology.

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

James X. Sun, P. Stephens, V. Miller, 2016, Clinical Cancer Research.

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

A. Drilon, F. Nicolantonio, A. Bardelli, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

James X. Sun, V. Miller, G. Frampton, 2018, Journal of gastrointestinal oncology.

Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.

S. Ou, V. Miller, Siraj M. Ali, 2017, The oncologist.

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Philip J. Stephens, James X. Sun, Garrett M. Frampton, 2016 .

Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI‐1)–Deficient Carcinomas of the Urinary System

J. Ross, N. Agarwal, V. Miller, 2017, Clinical genitourinary cancer.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples

James X. Sun, J. Gregg, P. Hegde, 2019, The Journal of molecular diagnostics : JMD.

Inactivation of Capicua drives cancer metastasis

S. Asthana, Matan Hofree, V. Miller, 2016, Nature Genetics.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

M. Ladanyi, M. Zauderer, R. Yelensky, 2016, The oncologist.

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.

S. Ou, Siraj M. Ali, K. Gowen, 2016, Lung cancer.